ReviewDermatologie (Heidelberg, Germany)2026
[New treatment options for autoimmune bullous diseases].
Review in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune bullous diseases are a heterogeneous group of diseases characterized by autoantibody deposits leading to split formation in the skin and mucous membranes; they are associated with a significant impairment of quality of life and increased mortality. Therapeutic options are limited and rely on broad immunosuppression, primarily the administration of topical or systemic glucocorticosteroids. Rituximab is also approved for moderate to severe pemphigus vulgaris. Due to the rarity of these conditions, the body of clinical research on pemphigus and pemphigoid diseases is limited. Current therapeutic approaches focus primarily on enhancing the efficacy of B‑cell depletion in pemphigus vulgaris/foliaceus, as well as on blocking specific inflammatory mediators in bullous pemphigoid. Further efforts are required to conduct more studies within this group of diseases and to fully realize the potential of more effective drugs with improved side-effect profiles.
Indexed as
Identifiers
42771162What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.